DANIEL TAVARI: Open Payments
NPI 1942240213 · THOUSAND OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,442 in 73 payments from 25 companies in 2025. Trend: 2023 $1,141 · 2024 $1,618 · 2025 $1,442
Food & beverage: $1,442
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $226 |
| Amgen Inc. | 9 | $213 |
| Novartis Pharmaceuticals Corporation | 5 | $95 |
| Astellas Pharma US Inc | 3 | $87 |
| GlaxoSmithKline, LLC. | 5 | $85 |
| Merck Sharp & Dohme LLC | 4 | $72 |
| Corcept Therapeutics | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Radius Health, Inc. | 3 | $67 |
| Aimmune Therapeutics, Inc. | 2 | $56 |
Products named: EVENITY, Veozah, REXULTI, QULIPTA, UBRELVY, Korlym, Tymlos, LEQVIO.
Industry payments across CA — which companies pay providers there.
